A Peek Into The Market Before The Trading Starts - Lennar (NYSE:LEN), Fluor (NYSE:FLR)

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

Pre-open moversUS stock futures are higher this morning, as investors are awaiting economic data. Futures for the Dow Jones Industrial Average surged 51 points to 14,639.00 and S&P 500 index futures rose 6.50 points to 1,572.70. Nasdaq 100 futures gained 12.75 points to 2,856.75.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

A Peek Into Global Markets European markets were higher today. The STOXX Europe 600 Index surged 1.12%, London's FTSE 100 index gained 0.83%, French CAC 40 Index climbed 1.42% and German DAX 30 index rose 1.41%.Asian markets ended mostly lower, with Japan's Nikkei Stock Average falling 0.72%, China's Shanghai Composite dropping 0.19% and Australia's ASX/S&P500 falling 0.38%. Hong Kong's Hang Seng Index gained 0.21% and India's Sensex surged 0.48%.Broker Recommendation

Analysts at Deutsche Bank downgraded Vanguard Health Systems (NYSE: VHS) from “buy” to “hold.” The target price for Vanguard Health has been raised from $16.50 to $21. Vanguard Health's shares closed at $20.70 yesterday. Breaking news

Fluor (NYSE: FLR) announced today that it was awarded a contract by Sasol Technology (Pty.) Ltd. to perform basic engineering services associated with the Natref Clean Fuels 2 Project in Sasolburg, South Africa. To read the full news, click here.
Lennar (NYSE: LEN) reported a drop in its second-quarter net income. To read the full news, click here.
Rite Aid (NYSE: RAD) today announced the completion of a portion of its previously announced debt refinancing transactions that extends the maturity on a portion of Rite Aid's outstanding indebtedness and lowers interest expense. To read the full news, click here.
Vical (NASDAQ: VICL) and Astellas Pharma today announced the initiation of a multinational Phase 3 registration trial of ASP0113 (TransVax™), in approximately 500 hematopoietic cell transplant (HCT) recipients. To read the full news, click here.